Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cognition Therapeutics ( (CGTX) ) has issued an update.
Cognition Therapeutics, Inc. received a deficiency letter from Nasdaq on September 12, 2024, due to its common stock price falling below the $1.00 minimum required by Nasdaq Listing Rule 5450(a)(1) for 30 consecutive trading days. However, by August 25, 2025, the company’s stock price had closed above $1.00 for more than ten consecutive days, leading Nasdaq to confirm on August 26, 2025, that Cognition Therapeutics had regained compliance with its listing requirements.
The most recent analyst rating on (CGTX) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Cognition Therapeutics stock, see the CGTX Stock Forecast page.
Spark’s Take on CGTX Stock
According to Spark, TipRanks’ AI Analyst, CGTX is a Neutral.
Cognition Therapeutics is currently facing major financial challenges with persistent losses and cash flow issues. Technical indicators provide mixed signals with short-term momentum but long-term caution. Valuation remains a concern with negative earnings and no dividend yield. Although the earnings call highlighted some strategic progress, significant concerns like NASDAQ compliance and uncertain funding overshadow these advancements. Overall, the stock is a high-risk investment with potential for future improvement if financial and strategic objectives are met.
To see Spark’s full report on CGTX stock, click here.
More about Cognition Therapeutics
Average Trading Volume: 10,424,576
Technical Sentiment Signal: Buy
Current Market Cap: $233.6M
See more data about CGTX stock on TipRanks’ Stock Analysis page.